EUCTR2018-002551-15-IT进行中（未招募）1 期
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma - NA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 132
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. written informed consent and privacy language as per national regulations (must be obtained from the subject or legally authorized representative prior to any study related procedures (including withdrawal of prohibited medication, if applicable).
- •2. Subject is considered an adult according to local regulation at the time of signing informed consent.
- •3. Subject agrees not to participate in another interventional study while receiving study drug in present study.
- •4. A female subject is eligible to participate if she is not pregnant or lactating and at least 1 of the following conditions applies:
- •¿ Not a woman of childbearing potential (WOCBP) as defined in the Protocol.
- •¿ WOCBP who agrees to follow the contraceptive guidance as defined in the Protocol throughout the treatment period and for at least 6 months after the final study drug administration.
- •5. Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 6 months after the final study drug administration.
- •6. Female subject must not donate ova starting at screening and throughout the study period, and for 6 months after the final study drug administration.
- •7. A male subject with female partner(s) of child-bearing potential must agree to use contraception as detailed in the Protocol during the treatment period and for at least 6 months after the final study drug administration.
- •8. A male subject must not donate sperm during the treatment period and for at least 6 months after the final study drug administration.
- •9. Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 6 months after the final study drug administration.
- •10. Subject has histologically or cytologically confirmed adenocarcinoma of pancreas.
- •11. Subjects must have metastatic pancreatic cancer that has not been previously treated with chemotherapy.
- •¿ Prior treatment with 5-FU or GEM administered as a radiation sensitizer during and up to 4 weeks after radiation therapy is allowed (if there is lingering toxicity, then the sponsor should be consulted).
- •¿ If a subject received therapy in the adjuvant setting, tumor recurrence or disease progression must have occurred at least 6 months after completing the last dose of adjuvant therapy.
- •12. Subject has a measurable lesion(s) on at least 1 metastatic site based on RECIST 1.1 within 28 days prior to the first dose of study treatment. For subjects with only 1 measureable lesion and prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must have documented progression following radiation therapy.
- •13. Subject's tumor sample has CLDN18.2 expression in = 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central IHC testing.
- •14. Subject has ECOG performance status of 0 or 1.
- •15. Subject has predicted life expectancy = 12 weeks in the opinion of the investigator.
- •16. Subject must meet all of the following criteria on the laboratory tests that will be analyzed centrally within 14 days prior to the first dose of study drug. In case of multiple laboratory data within this period, the most recent data should be used.
- •Hemoglobin = 9 g/dl (no transfusion within 14 days of start of study
- •Absolute neutrophil count = 1.5 x 109 /L
- •Platelets = 100 x 109 /L
- •Albumin = 2.5 g/dL
- •Total bilirubin = 1.5 x upper limi
排除标准
- •Subject will be excluded from participation if any of the following apply:
- •Prohibited Treatment or Therapies
- •1. Subject has received other investigational treatment within 28 days
- •prior to screening.
- •2. Subject has received radiotherapy for metastatic pancreatic adenocarcinoma within 28 days prior to the first dose of study
- •treatment. Subject who received palliative radiotherapy to peripheral bone metastases = 14 days prior to first dose of study treatment and has recovered from all acute toxicities is eligible.
- •3. Subject has received systemic immunosuppressive therapy, including systemic corticosteroids within 14 days prior to first dose of study treatment.
- •Subject using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone) or a single dose of systemic corticosteriods is eligible.
- •4. Subject has prior severe allergic reaction or intolerance to known ingredients of zolbetuximab or other monoclonal antibody, including humanized or chimeric antibodies.
- •5. Subject has known immediate or delayed hypersensitivity, intolerance
- •contraindication to any component of study treatment.
- •6. Subject has a known history of a positive test for human immunodeficiency virus infection or known active Hepatitis B (positive HBs antigen [Ag]) or Hepatitis C infection. For subjects who are negative for HBs Ag, but Hepatitis B core antibody positive, a Hepatitis B virus DNA test will be performed and if positive, the subject will be excluded. Subjects with
- •positive serology but negative Hepatitis C virus RNA test results are eligible.
- •7. Subject has a history of interstitial pneumonia or pulmonary fibrosis.
- •8. Subject has pleural effusion or ascites = Grade 3 per CTCAE v 4.0.
- •9. Subject has an active autoimmune disease that has required systemictreatment in the past 2 years.
- •10. Subject has active infection requiring systemic therapy that has not completely resolved per investigator judgment within 14 days prior to first dose of study treatment.
- •11. Subject has significant cardiovascular disease, including:
- •¿ Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, coronary stenting, coronary artery bypass graft, cerebrovascular accident or hypertensive crisis within 6 months prior to administration of first dose of study treatment;
- •¿ History of clinically significant ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes);
- •¿ QTc interval > 450 msec for male subjects; QTc interval > 470 msec for female subjects;
- •¿ Cardiac arrhythmias requiring anti-arrhythmic medications (Subjects
- •with rate controlled atrial fibrillation for > 1 month prior to first dose of study
- •treatment are eligible.)
- •12. Subject has known active or treated central nervous system metastases and/or carcinomatous meningitis.
- •13. Subject has known peripheral sensory neuropathy = Grade 2 per CTCAE v.4.0 unless the absence of deep tendon reflexes is the sole neurological abnormality.
- •14. Subject has had a major surgical procedure = 28 days prior to the first dose of study drug.
- •15. Subject without complete recovery from a major surgical procedure = 14 days prior to the first dose of study treatment.
- •16. Psychiatric illness or social situations that would preclude study compliance per investigator's judgment.
- •17. Subject has another malignancy for
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to evaluate a new medicine (Zolbetuximab) for the treatment of pancreatic cancerFirst Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic AdenocarcinomaMedDRA version: 20.0 Level: LLT Classification code 10033599 Term: Pancreatic adenocarcinoma metastatic System Organ Class: 100000004864EUCTR2018-002551-15-ESAstellas Pharma Global Development, Inc. (APGD)141
进行中（未招募）
1 期
A clinical trial to evaluate a new medicine (Zolbetuximab) for the treatment of pancreatic cancer.First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma.MedDRA version: 21.0Level: LLTClassification code: 10033599Term: Pancreatic adenocarcinoma metastatic Class: 10029104CTIS2024-510985-17-00Astellas Pharma Global Development Inc.396
进行中（未招募）
1 期
A clinical trial to evaluate a new medicine (Zolbetuximab) for the treatment of pancreatic cancerFirst Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic AdenocarcinomaMedDRA version: 20.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2018-002551-15-FRAstellas Pharma Global Development, Inc. (APGD)141
进行中（未招募）
1 期
A clinical trial to evaluate a new medicine (Zolbetuximab) for the treatment of pancreatic cancerFirst Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic AdenocarcinomaMedDRA version: 21.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2018-002551-15-IEAstellas Pharma Global Development, Inc. (APGD)369
进行中（未招募）
1 期
A Clinical Study to evaluate the efficacy and safety of GS-5745 in combination with Nivolumab compared to Nivolumab alone in patients with stomach cancerEUCTR2016-001402-41-HUGilead Sciences, Inc144